Statins as regulators of redox signaling in platelets

Antioxidants and Redox Signaling

Volumn 20, Issue 8, 2014, Pages 1300-1312

  Violi, Francesco ^a   Pignatelli, Pasquale ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIOXIDANTS; BLOOD PLATELETS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATION-REDUCTION; PLATELET ACTIVATION; SIGNAL TRANSDUCTION;

EID: 84894469411     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5527     Document Type: Review

References (102)

1. Adler DH, Cogan JD, Phillips JA, 3rd, Schnetz-Boutaud N, Milne GL, Iverson T, Stein JA, Brenner DA, Morrow JD, Boutaud O, and Oates JA. Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest 118: 2121-2131, 2008.
2. Alber HF, Frick M, Suessenbacher A, Doerler J, Schirmer M, Stocker EM, Dichtl W, Pachinger O, and Weidinger F. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease-a randomized, placebocontrolled study. Am Heart J 151: 139, 2006.
3. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, and Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8: 247-252, 2002.
4. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002.
5. Arthur JF, Qiao J, Shen Y, Davis AK, Dunne E, Berndt MC, Gardiner EE, and Andrews RK. ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and Syk-independent pathways. J Thromb Haemost 10: 1133-1141, 2012.
6. Basili S, Pignatelli P, Tanzilli G, Mangieri E, Carnevale R, Nocella C, Di Santo S, Pastori D, Ferroni P, and Violi F. Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 31: 1766-1771, 2011.
7. Bea F, Blessing E, Shelley MI, Shultz JM, and Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 167: 187-194, 2003.
8. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B, and Walter U. Platelet NAD(P)H-oxidasegenerated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood 106: 2757-2760, 2005.
9. Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, and Lip GY. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 88: A7-A8; 89-92, 2001.
10. Bou Khzam L, Hachem A, Zaid Y, Boulahya R, Mourad W, and Merhi Y. Soluble CD40 ligand impairs the anti-platelet function of peripheral blood angiogenic outgrowth cells via increased production of reactive oxygen species. Thromb Haemost 109: 940-947, 2013.
11. Brass LF, Zhu L, and Stalker TJ. Minding the gaps to promote thrombus growth and stability. J Clin Invest 115: 3385-3392, 2005.
12. Cangemi R, Pignatelli P, Carnevale R, Nigro C, Proietti M, Angelico F, Lauro D, Basili S, and Violi F. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 61: 1626-1632, 2012.
13. Carnevale R, Loffredo L, Pignatelli P, Nocella C, Bartimoccia S, Di Santo S,Martino F, Catasca E, Perri L, and Violi F. Dark chocolate inhibits platelet isoprostanes via NOX2 downregulation in smokers. J Thromb Haemost 10: 125-132, 2012.
14. Carter NJ. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. Am J Cardiovasc Drugs 10: 383-400, 2010.
15. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24: 1980-1987, 2004.
16. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, and Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8: 691-728, 2006.
17. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, and Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 25: 2428-2434, 2005.
18. Chou TC, Lin YF, Wu WC, and Chu KM. Enhanced nitric oxide and cyclic GMP formation plays a role in the antiplatelet activity of simvastatin. Br J Pharmacol 153: 1281-1287, 2008.
19. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, Vered Z, Krakover R, Kaluski E, and Kornberg A. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 147: 293-300, 2004.
20. Das DK, Sato M, Ray PS, Maulik G, Engelman RM, Bertelli AA, and Bertelli A. Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res 25: 115-120, 1999.
21. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, and Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229, 1999.
22. Davi G and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357: 2482-2494, 2007.
23. Dayal S, Wilson KM, Motto DG, Miller FJ, Jr., Chauhan AK, and Lentz SR. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation 127: 1308-1316, 2013.
24. De Curtis A, Murzilli S, Di Castelnuovo A, Rotilio D, Donati MB, De Gaetano G, and Iacoviello L. Alcohol-free red wine prevents arterial thrombosis in dietary-induced hypercholesterolemic rats: experimental support for the 'French paradox'. J Thromb Haemost 3: 346-350, 2005.
25. de Lange DW and van de Wiel A. Drink to prevent: review on the cardioprotective mechanisms of alcohol and red wine polyphenols. Semin Vasc Med 4: 173-186, 2004.
26. Del Principe D, Menichelli A, De Matteis W, Di Giulio S, Giordani M, Savini I, and Agro AF. Hydrogen peroxide is an intermediate in the platelet activation cascade triggered by collagen, but not by thrombin. Thromb Res 62: 365-375, 1991.
27. Demrow HS, Slane PR, and Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 91: 1182-1188, 1995.
28. Du X, Gu M, Weisel JW, Nagaswami C, Bennett JS, Bowditch R, and Ginsberg MH. Long range propagation of conformational changes in integrin alpha IIb beta 3. J Biol Chem 268: 23087-23092, 1993.
29. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, and Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 117: 953-960, 2007.
30. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, and Furie BC. Glycoprotein VI-dependent and-independent pathways of thrombus formation in vivo. Blood 107: 3902-3906, 2006.
31. Evangelista V, Manarini S, Dell'Elba G, Martelli N, Napoleone E, Di Santo A, and Lorenzet PS. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 94: 568-577, 2005.
32. Ferreiro JL, Gomez-Hospital JA, and Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 7: 251-259, 2010.
33. Ferroni P, Vazzana N, Riondino S, Cuccurullo C, Guadagni F, and Davi G. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal 17: 1447-1485, 2012.
34. Fontana G, Ware J, and Cattaneo M. Haploinsufficiency of the platelet P2Y12 gene in a family with congenital bleeding diathesis. Haematologica 94: 581-584, 2009.
35. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol 28: s11-s16, 2008.
36. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, and Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34: 551-557, 2003.
37. Goto S, Ikeda Y, Saldivar E, and Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 101: 479-486, 1998.
38. Holtkotter O, Nieswandt B, Smyth N, Muller W, Hafner M, Schulte V, Krieg T, and Eckes B. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 277: 10789-10794, 2002.
39. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, and Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85: 357-363, 1999.
40. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265-9269, 1987.
41. Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J 144: S27-S32, 2002.
42. Jin RC, Mahoney CE, Coleman Anderson L, Ottaviano F, Croce K, Leopold JA, Zhang YY, Tang SS, Handy DE, and Loscalzo J. Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo. Circulation 123: 1963-1973, 2011.
43. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, and Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100: 917-924, 2002.
44. Krotz F, Sohn HY, and Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 24: 1988-1996, 2004.
45. Leo R, Pratico D, Iuliano L, Pulcinelli FM, Ghiselli A, Pignatelli P, Colavita AR, FitzGerald GA, and Violi F. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation 95: 885-891, 1997.
46. Liu Y, Davidson BP, Yue Q, Belcik T, Xie A, Inaba Y, McCarty OJ, Tormoen GW, Zhao Y, Ruggeri ZM, Kaufmann BA, and Lindner JR. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging 6: 74-82, 2013.
47. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans 31: 1059-1061, 2003.
48. Ludman A, Venugopal V, Yellon DM, and Hausenloy DJ. Statins and cardioprotection-more than just lipid lowering? Pharmacol Ther 122: 30-43, 2009.
49. Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan Y, Schoenwaelder SM, Wright CE, Lanza F, and Jackson SP. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood 107: 4346-4353, 2006.
50. Marcus AJ, Broekman MJ, and Pinsky DJ. COX inhibitors and thromboregulation. N Engl J Med 347: 1025-1026, 2002.
51. Marcus AJ, Silk ST, Safier LB, and Ullman HL. Superoxide production and reducing activity in human platelets. J Clin Invest 59: 149-158, 1977.
52. Matetzky S, Fefer P, Shenkman B, Shechter M, Novikov I, Savion N, Varon D, and Hod H. Statins have an early antiplatelet effect in patients with acute myocardial infarction. Platelets 22: 103-110, 2011.
53. Mehta JL, Chen LY, Kone BC, Mehta P, and Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 125: 370-377, 1995.
54. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; Investigators T-T. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373: 723-731, 2009.
55. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J, Waclawczyk T, Ulczok R, and Bochenek A. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 130: 791-796, 2005.
56. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25: 279-286, 2005.
57. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, and Roberts LJ, 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87: 9383-9387, 1990.
58. Moscardo A, Valles J, Latorre A, Madrid I, and Santos MT. Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Thromb Res 131: e154-e159, 2013.
59. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, and Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 106: 385-392, 2000.
60. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, and Fassler R. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 20: 2120-2130, 2001.
61. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, and Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 15: 247-251, 1995.
62. Obi C, Wysokinski W, Karnicki K, Owen WG, and McBane RD, 2nd. Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMGCoA reductase therapy. Arterioscler Thromb Vasc Biol 29: 1271-1276, 2009.
63. Palmer RM, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature 327: 524-526, 1987.
64. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A, Yun KH, Jeong MH, Kim JS, Choi D, Bozbas H, Kinoshita M, Fukuda K, Jia XW, Hara H, Cay S, and Di Sciascio G. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 123: 1622-1632, 2011.
65. Perez-Jimenez J, Neveu V, Vos F, and Scalbert A. Identification of the 100 richest dietary sources of polyphenols: an application of the Phenol-Explorer database. Eur J Clin Nutr 64 Suppl 3: S112-S120, 2010.
66. Phillips DR, Fitzgerald LA, Charo IF, and Parise LV. The platelet membrane glycoprotein IIb/IIIa complex. Structure, function, and relationship to adhesive protein receptors in nucleated cells. Ann N Y Acad Sci 509: 177-187, 1987.
67. Pieper GM, Nilakantan V, Nguyen TK, Hilton G, Roza AM, and Johnson CP. Reactive oxygen and reactive nitrogen as signaling molecules for caspase 3 activation in acute cardiac transplant rejection. Antioxid Redox Signal 10: 1031-1040, 2008.
68. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Nocella C, Vicario T, Loffredo L, Angelico F, and Violi F. Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. Biochem Pharmacol 84: 1635-1642, 2012.
69. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Sanguigni V, Lenti L, Finocchi A, Mendolicchio L, Soresina AR, Plebani A, and Violi F. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 31: 423-434, 2011.
70. Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, and Violi F. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 126: 92-103, 2012.
71. Pignatelli P, Di Santo S, Barilla F, Gaudio C, and Violi F. Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. J Thromb Haemost 6: 1832-1834, 2008.
72. Pignatelli P, Ghiselli A, Buchetti B, Carnevale R, Natella F, Germano G, Fimognari F, Di Santo S, Lenti L, and Violi F. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis 188: 77-83, 2006.
73. Pignatelli P, Lenti L, Pulcinelli FM, Catasca R, Saccani G, Germano G, Marcoccia A, Silvestri MA, Ghiselli A, and Violi F. Red and white wine differently affect collagen-induced platelet aggregation. Pathophysiol Haemost Thromb 32: 356-358, 2002.
74. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, and Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 91: 484-490, 1998.
75. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, and Violi F. Vitamin E inhibits collagen-induced platelet activation by blunting hydrogen peroxide. Arterioscler Thromb Vasc Biol 19: 2542-2547, 1999.
76. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, and Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 110: 1326-1329, 2004.
77. Pignatelli P, Sanguigni V, Lenti L, Loffredo L, Carnevale R, Sorge R, and Violi F. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost 5: 1170-1178, 2007.
78. Pluta RM, Rak R, Wink DA, Woodward JJ, Khaldi A, Oldfield EH, and Watson JC. Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury. Neurosurgery 48: 884-892; discussion 892-893, 2001.
79. Pratico D, Smyth EM, Violi F, and FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 271: 14916-14924, 1996.
80. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, and Bruni F. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 32: 901-908, 2002.
81. Pucci A, Sheiban I, Formato L, Celeste A, Brscic E, Moretti C, De Bernardi A, Alberti A, Bergamasco L, Trevi G, and Fuster V. In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. Atherosclerosis 194: 189-195, 2007.
82. Rodvein R, Lindon JN, and Levine PH. Physiology and ultrastructure of the blood platelet following exposure to hydrogen peroxide. Br J Haematol 33: 19-26, 1976.
83. Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 105: 699-701, 2000.
84. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI, Kawashima S, Tawa R, Imajoh-Ohmi S, Sakurai H, and Yokoyama M. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 103: 399-409, 2001.
85. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay JF, and Hennekens CH. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 97: 1332-1336, 2006.
86. Sommeijer DW, Joop K, Leyte A, Reitsma PH, and ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 3: 1168-1171, 2005.
87. Steiner M. Vitamin E and the risk of coronary disease. N Engl J Med 329: 1424-1425; author reply 1425-1426, 1993.
88. Steiner M, Glantz M, and Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 62: 1381S-1384S, 1995.
89. Sugamura K and Keaney JF, Jr. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 51: 978-992, 2011.
90. Tannous M, Cheung R, Vignini A, and Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 82: 1390-1394, 1999.
91. Tozzi Ciancarelli MG, Di Massimo C, De Amicis D, Ciancarelli I, and Carolei A. Moderate consumption of red wine and human platelet responsiveness. Thromb Res 128: 124-129, 2011.
92. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232-235, 1971.
93. Violi F and Pignatelli P. Aspirin resistance: is this term meaningful? Curr Opin Hematol 13: 331-336, 2006.
94. Violi F and Pignatelli P. Platelet oxidative stress and thrombosis. Thromb Res 129: 378-381, 2012.
95. Violi F, Pignatelli P, and Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation 121: 1033-1044, 2010.
96. Violi F, Sanguigni V, Loffredo L, Carnevale R, Buchetti B, Finocchi A, Tesauro M, Rossi P, and Pignatelli P. Nox2 is determinant for ischemia-induced oxidative stress and arterial vasodilatation: a pilot study in patients with hereditary Nox2 deficiency. Arterioscler Thromb Vasc Biol 26: e131-e132, 2006.
97. Vu TK, Hung DT, Wheaton VI, and Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068, 1991.
98. Wachowicz B, Olas B, Zbikowska HM, and Buczynski A. Generation of reactive oxygen species in blood platelets. Platelets 13: 175-182, 2002.
99. Williams HC and Griendling KK. NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol 50: 9-16, 2007.
100. Winchester DE, Wen X, Xie L, and Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol 56: 1099-1109, 2010.
101. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Katoh A, and Imaizumi T. HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting plateletderived nitric oxide release in rats. J Cardiovasc Pharmacol 45: 375-381, 2005.
102. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502, 2001